Core Insights - Beijing Baipusais Biotechnology Co., Ltd. reported a significant increase in revenue and net profit for the first three quarters of 2025, with revenue reaching 613 million yuan, a year-on-year growth of 32.26%, and net profit attributable to shareholders amounting to 132 million yuan, a year-on-year increase of 58.61% [1] - In the third quarter alone, the company achieved revenue of 226 million yuan, reflecting a year-on-year growth of 37.50%, and a net profit of 48.62 million yuan, which is an impressive year-on-year increase of 81.46% [1] Financial Performance - Total revenue for the first three quarters of 2025: 613 million yuan, up 32.26% year-on-year [1] - Net profit for the first three quarters: 132 million yuan, up 58.61% year-on-year [1] - Third quarter revenue: 226 million yuan, up 37.50% year-on-year [1] - Third quarter net profit: 48.62 million yuan, up 81.46% year-on-year [1] Strategic Initiatives - The company announced plans to initiate the issuance of H-shares and list on the Hong Kong Stock Exchange to enhance its international strategy, expand overseas business, and improve overall competitiveness [1] - The board of directors has authorized the management to start the preparatory work for the H-share issuance and listing [1]
百普赛斯前三季度实现营业收入6.13亿元 拟境外发行股份并赴港上市